Insights

Gathering insights about Cognition…

Similar companies to Cognition

Cognition Tech Stack

Cognition uses 8 technology products and services including Drupal, WP Engine, C#, and more. Explore Cognition's tech stack below.

Drupal
Content Management System
WP Engine
Platform As A Service
C#
Programming Languages
Java
Programming Languages
JavaScript
Programming Languages
All in One SEO
Search Engines
Adobe Creative Suite
Visualisation Software
Apache
Web Servers

Media & News

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
PURCHASE, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has extended the duration of the expanded access program (EAP) for dementia with Lewy bodies (DLB). The program, which was originally expected to provide each participant with twelve months of treatment, will now allow several more months of treatment.
Feb 05, 2026 | www.globenewswire.com
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
PURCHASE, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a Type C meeting with the U.S. Food and Drug Administration (FDA) on January 21, 2026. The objective of this meeting was to review plans for the proposed Phase 2b study of zervimesine in dementia with Lewy bodies (DLB), a disease with no FDA-approved therapies.
Jan 27, 2026 | www.globenewswire.com
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies
- Zervimesine exhibited meaningful improvement in behavioral, functional, cognitive, and movement measures compared to placebo - - Zervimesine exhibited meaningful improvement in behavioral, functional, cognitive, and movement measures compared to placebo -
Jan 06, 2026 | www.globenewswire.com
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference
- Seeking Alignment with European Medicines Agency (EMA) at February 2026 Meeting - - Actively Evaluating Strategy Across DLB and Alzheimer's Disease -
Dec 01, 2025 | www.globenewswire.com
Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference
PURCHASE, N.Y., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi will participate in an “unplugged” fireside discussion at the annual Piper Sandler Healthcare Conference. The conference will take place December 2-4, 2025 at The Lotte New York Palace hotel.
Nov 20, 2025 | www.globenewswire.com
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer's Disease
Study conducted in collaboration with the Alzheimer's Clinical Trials Consortium Study conducted in collaboration with the Alzheimer's Clinical Trials Consortium
Nov 13, 2025 | www.globenewswire.com
Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
- $30 Million Registered Direct Offering Support Next Stage of Development for Zervimesine (CT1812) - - Aligned with U.S. FDA on Registrational Path for Zervimesine - - Expanded Access Program for Dementia with Lewy Bodies Ongoing - PURCHASE, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today reported financial results for the third quarter ended September 30, 2025, and provided a business update.
Nov 06, 2025 | www.globenewswire.com

Cognition's Email Address Formats

Cognition uses at least 1 format(s):

Cognition Email Formats	Example	Percentage
First@cognitionstudio.com	John@cognitionstudio.com	46%
First.Last@cognitionstudio.com	John.Doe@cognitionstudio.com	7%
Last.F@cognitionstudio.com	Doe.J@cognitionstudio.com	1%
First@cognitionstudio.com	John@cognitionstudio.com	46%

Frequently Asked Questions

Where is Cognition's headquarters located?

Cognition's main headquarters is located at 1118 Northwest 50th Street Suite 200 Seattle, Washington 98107 United States. The company has employees across 2 continents, including North AmericaAsia.

What is Cognition's phone number?

You can contact Cognition's main corporate office by phone at

+1-206-382-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Cognition's stock symbol?

Cognition is a publicly traded company; the company's stock symbol is CGTX.

What is Cognition's official website and social media links?

Cognition's official website is cognitionstudio.com and has social profiles on LinkedIn.

How much revenue does Cognition generate?

As of February 2026, Cognition's annual revenue is estimated to be $500K.

What is Cognition's SIC code NAICS code?

Cognition's SIC code is 7336 - Commercial Art and Graphic Design NAICS code is 5414 - Specialized Design Services.

How many employees does Cognition have currently?

As of February 2026, Cognition has approximately 29 employees across 2 continents, including North AmericaAsia. Key team members include Chief Financial Officer: R. S.President: D. S.Associate Director Of Design, User Experience: J. C.. Explore Cognition's employee directory with LeadIQ.

What industry does Cognition belong to?

Cognition operates in the Design Services industry.

What technology does Cognition use?

Cognition's tech stack includes DrupalWP EngineC#JavaJavaScriptAll in One SEOAdobe Creative SuiteApache.

What is Cognition's email format?

Cognition's email format typically follows the pattern of First@cognitionstudio.com. Find more Cognition email formats with LeadIQ.

When was Cognition founded?

Cognition was founded in 2001.

Cognition

Q: What is Cognition's official website and social media links?

Cognition's official website is cognitionstudio.com. Cognition has social profiles on LinkedIn.

Q: How many employees does Cognition have currently?

Cognition has approximately 29 employees.

Q: What technology does Cognition use?

Cognition's tech stack includes C#, HTTP/3, Lodash, Cloudflare, npm.

Design ServicesWashington, United States11-50 Employees

Cognition is a strategy + visual communication firm for life sciences. We help organizations build trust and knowledge in new science, research, and medicines.

Our expertise lies in creating accurate scientific storytelling, strong brands, and human-centered solutions to create value for emerging medical technology, research, and healthcare.

Our centers of excellence are in biotechnology (biologics), venture capital (NewCos and GrowthCos), and global health (platforms, products & services).

Company Overview

Headquarters: 1118 Northwest 50th Street Suite 200 Seattle, Washington 98107 United States
Phone number: +1-206-382-****
Website: cognitionstudio.com
SIC Code: 7336 - Commercial Art and Graphic Design
Stock Symbol: CGTX
NAICS Code: 5414 - Specialized Design Services
Founded: 2001
Employees: 11-50

Media & News

Funding & Financials

$25M$50M
Cognition's revenue is estimated to be in the range of $25M$50M

Funding & Financials

$25M$50M
Cognition's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Cognition

Cambridge Cognition

Cogniciti

Pear Therapeutics

Clarifai

Cognoa

VeriSIM Life

Neurotrack

AiCure

Cogstate

Cognition Tech Stack

Media & News

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference

Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference

Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer's Disease

Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs

Cognition's Email Address Formats

Frequently Asked Questions

Where is Cognition's headquarters located?

What is Cognition's phone number?

What is Cognition's stock symbol?

What is Cognition's official website and social media links?

How much revenue does Cognition generate?

What is Cognition's SIC code NAICS code?

How many employees does Cognition have currently?

What industry does Cognition belong to?

What technology does Cognition use?

What is Cognition's email format?

When was Cognition founded?

Cognition

Company Overview

Media & News

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?